Crescent Biopharma Earnings Call Transcripts
Fiscal Year 2026
-
The session highlighted a robust oncology pipeline with CR-001 as a potential next-generation backbone therapy, supported by innovative ADC combinations and a strong partnership with Kelun-Biotech. Key data readouts are expected in 2027, with a financial runway into 2028 and a focus on rapid, data-driven expansion across major cancer indications.
-
HARMONi-6 and related data validate PD-1/VEGF bispecifics as a new backbone in immuno-oncology, showing strong efficacy and safety across tumor types. Strategic trial design, global considerations, and robust partnerships, especially with Kelun-Biotech, are driving pipeline expansion and positioning for leadership in the field.
-
The meeting confirmed the election of two directors, ratified the auditor, and approved executive compensation and annual advisory votes on compensation. No shareholder questions were raised, and final vote results will be published in the minutes and Form 8-K.
-
The company is advancing a matrix portfolio of IO bispecifics and ADCs, with four clinical studies launching this year and major data readouts expected in 2027. Key programs include CR-001, designed to improve upon ivonescimab, and CR-003, targeting integrin beta-6. Strategic partnerships and robust financing support execution.
-
The company is advancing a next-generation oncology portfolio with a focus on synergistic IO and ADC combinations, supported by a key partnership with Kelun. Comprehensive global trials and upcoming data readouts in 2027 will guide indication selection and registration strategies, with a strong financial position enabling execution.
-
The team is advancing a dual strategy in oncology with a next-gen bispecific and ADC portfolio, targeting robust data readouts by 2027. Global trials and a key partnership with Kelun-Biotech are accelerating development and supporting broad indication coverage.
-
The company is advancing a diversified oncology portfolio, highlighted by a PD-1/VEGF bispecific and multiple ADCs, with a strategic partnership enabling parallel data generation in China and globally. Key clinical readouts are expected in 2027, supported by strong funding and a focus on best-in-class differentiation.
-
The company is advancing a robust oncology pipeline, highlighted by CR-001 and strategic ADC assets, with multiple studies launching and key data readouts expected in 2027. Strong partnerships and financial position support a data-driven, combination-focused development strategy.
-
A robust oncology portfolio is advancing with global clinical trials for CR-001 and differentiated ADCs, supported by a strong financial position and strategic partnerships. Key data readouts are expected from 2027, with combination studies and industry catalysts shaping future development.
Fiscal Year 2025
-
A strategic partnership with Kelun-Biotech accelerates development of IO and ADC therapies, enabling parallel clinical trials in the US, Europe, and China. Four clinical trials are set for 2026, with multiple data readouts expected in 2027, supported by a $185M capital raise.
-
A dual strategy centers on CR001 (PD-1 VEGF bispecific) and an ADC pipeline, with global phase I trials for CR001 starting soon and CR002 to follow. The company leverages industry data, aims for rapid clinical expansion, and is well-funded through 2027.
-
Management outlined a dual strategy focused on a next-gen IO backbone (CR-001) and best-in-class ADC combinations, with CR-001 entering clinical trials soon and proof-of-concept data expected by late 2026 or early 2027. The company is well-capitalized, leveraging robust preclinical data and global trial design to accelerate development and de-risk programs.
-
A dual strategy is being pursued with a PD1 VEGF bispecific and ADC pipeline, targeting robust clinical development and differentiation in a competitive oncology market. Phase I trials for CR001 will begin early next year, with strong financial runway through 2027 and a focus on high-quality data to drive partnerships and expansion.
-
A dual immuno-oncology and ADC strategy is driving rapid clinical development, with CR-001 set for first patient dosing in Q1 2026 and key data expected by early 2027. Strong validation from recent industry data, robust cash runway, and a focus on global expansion position the company for leadership in the bi-specific and ADC space.
-
Focused on building a leading oncology franchise, the company is advancing a VEGF/PD-1 bispecific antibody (CR-001) and ADC programs, with global clinical trials and a strong cash runway through 2027. The strategy leverages proven structures, aims for differentiation, and maintains flexibility for partnerships.